Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S. Jhund, Michele Senni, Martin P. Lefkowitz, Margaret F. Prescott, Victor C. Shi, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, Milton Packer, Akshay S. Desai, Scott D. Solomon and John J.V. McMurray
(A) Primary outcome by treatment group and chronic kidney disease (CKD) status at screening. (B) Primary outcome by treatment group and urinary albumin to creatinine ratio (UACR) value at 30 days after randomization. The arrow indicates the median UACR change (0.30 mg/mmol) seen with sacubitril/valsartan compared with enalapril, and the dotted lines represent the corresponding incidence rate of cardiovascular death or hospitalization for heart failure.